** Shares of cancer diagnostic test maker Grail GRAL.O fall 18.8% to $34.81 in extended trading
** Company's Q1 revenue of $31.8 million misses analysts' average expectation of $35.2 million, according to data compiled by LSEG
** GRAL reports quarterly loss of $3.10/shr, vs analysts' average estimate of $4.09/shr
** Up to last close, stock up more than double YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。